HER2/Neu陽性転移性乳がん患者に対する化学療法とラパチニブまたはトラスツズマブの併用

基本情報

NCT ID

NCT00667251

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

652

治験依頼者名

Novartis

概要

This was a multi-center, multinational, randomized, open-label, Phase III study comparing combination taxane-based chemotherapy plus lapatinib to combination taxane-based chemotherapy plus trastuzumab in women with documented evidence of human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer (MBC) (by local or central laboratory testing) who had received no prior chemotherapy or HER2 targeted therapy in the metastatic setting.

対象疾患

介入

依頼者（Sponsor）